therapeutic drugs may provide an improved alternative to conventional chemotherapy [14, 16-18]. Satyamaheshwar Peddibhotla, The mammalian nuclear transcription factor, NF-κB, and Jetze J. Tepe* is a multisubunit complex involved in the regulation of Department of Chemistry gene transcription, including the regulation of apo-Michigan State University ptosis [19, 20]. Five distinct subunits of NF-κB are East Lansing, Michigan 48824 found in mammalian cells, which include NF-κB1 (p105/ p50), NF-κB2 (p100/p52), RelA (p65), RelB, and c-Rel [20]. These subunits can compose a variety of homo-Summary or heterodimers, which are used to control the specificity and selectivity of certain DNA control elements [21, Activation of nuclear transcription factor B (NF-B) 22]. In most unstimulated mammalian cells, NF-κB exists mainly as a homodimer (p50/p50) or heterodimer by chemotherapeutic agents was found to protect (p50/p65) in the cytoplasm in the form of an inactive cells from apoptosis. In light of its central role in regucomplex with the inhibitory protein I-κB (Figure 1). lating the cellular resistance to apoptotic agents, inhi-Many cellular stimuli, including antineoplastic agents bition of NF-B-mediated gene transcription may sen-[23-31], viruses (e.g., HIV), cytokines, phorbol esters, sitize tumor cells to chemotherapeutic agents and and oxidative stress, result in the IKK-mediated phosenhance their efficacy. We describe herein a noncytophorylation of I-κB on serines 32 and 36, followed by toxic imidazoline scaffold that sensitizes leukemia T ubiquitinylation and subsequent degradation by the 26 cells to the chemotherapeutic agent camptothecin. S proteosome [19]. Degradation of I-κB ensures the re-No significant induction of apoptosis was found when lease of NF-κB. [32] Upon release, NF-κB translocates cells were treated with the imidazoline; however, preinto the nucleus, where the subunits bind with specific treatment of cells with this agent resulted in a drastic DNA control elements and initiate gene transcription enhancement in efficacy of camptothecin (w75-fold). (Figure 1). Prior to DNA binding, additional protein Elucidation of the potential cellular mechanism rephosphorylation events are required for optimal and vealed that the imidazoline prevents nuclear translocaspecific gene transcription [33-36]. Antiapoptotic genes tion of NF-B. These findings indicate that inhibition of such as TRAF1, TRAF2, c-IAP1, c-IAP2, XIAP, and IEX-NF-B by this imidazoline may present improved stra-1L are directly regulated by NF-κB and abrogate the tegies in the chemotherapeutic treatment of cancer. apoptotic signals in response to the chemotherapeutic agents [10, 37]. Introduction The antitumor agent camptothecin (CPT) is an alkaloid isolated from the extracts of the fruit of Camptotheca Apoptosis or programmed cell death is a cellular mechacuminata and was identified as a topoisomerase I inhibianism used to regulate cell number and eliminate damtor [38, 39]. CPT-11 and several water-soluble analogs aged or mutated cells [1, 2]. Alterations in apoptotic including topotecan have successfully passed clinical pathways can disrupt the delicate balance between cell trials in the United States [40]. Camptothecin exhibits its antitumor activity via the formation of a stable terproliferation and cell death, leading to a variety of disnary topoisomerase I-DNA cleavable complex [38, 41]. eases [3, 4]. In many cancers, apoptosis is abnormally Stabilization of this cleaved DNA complex initiates an downregulated, either by the mutation of proapoptotic apoptotic signaling pathway, ultimately resulting in cell proteins or by the upregulation of antiapoptotic prodeath [38, 42]. Concomitant with the initiation of this teins [5]. Aberrant apoptosis provides an intrinsic surapoptotic cell signal, these agents induce antiapoptotic vival advantage to cancer cells, causing growth and signaling pathways, which have compromised their effiexpansion of the tumor as well as resistance to procacy in the clinic [26, 43-45]. This cellular resistance apoptotic signals such as chemotherapeutic agents [6, has been attributed to the activation of antiapoptotic 7]. In addition, chemotherapeutic agents may also insignaling pathways mediated by several transcription duce secondary antiapoptotic factors, thereby adding factors, in particular the nuclear transcription factor, to this intrinsic resistance to chemotherapy [8-11]. The NF-κB [11, 28, 46]. combination of these antiapoptotic mechanisms has cDNA microarrays on HeLa cells using all annotated resulted in an increased dose intensity of chemotherahuman genes have been used to establish the associapeutics, often without the anticipated improved theration between characteristic gene expression patterns peutic results. [12] The search for new chemotherapeuin response to camptothecin [47, 48]. These studies in tic strategies has therefore shifted to small molecules HeLa cells provided striking support that administration that can selectively induce apoptosis in cancer cells or of camptothecin resulted in upregulation in a large retard the cellular chemoresistance [13-15]. Strategies number of genes controlled by NF-κB [47]. NF-κB's meusing combinations of inducers of apoptosis and/or indiated antiapoptotic response induced by DNA-damaghibitors of antiapoptotic factors and traditional chemoing agents may also result in the induction of cellular DNA repair mechanisms [49]. Topoisomerase inhibitors are in this context also considered DNA-damaging
. General NF-κB Activation Pathway by Chemotherapeutic Agents agents, since they exert their cytotoxicity via the stabili-thecin [54] . These pioneering studies illustrated the clinical potential of NF-κB inhibitors in combination zation of a ternary DNA-drug-protein cleavable complex [42] . In addition to the induction of antiapoptotic chemotherapy. There are numerous natural and synthetic inhibitors of NF-κB reported in the literature [55] , gene transcription, the topoisomerase I inhibitor camptothecin was found to induce the NF-κB-mediated acti-which include many antioxidants such as pyrrolinedithiocarbamate or PDTC, [ Figure 1 ). Since PS-341 exhibits significant cell cytotoxicity, it may be used as a single agent or in I-κBα regulated the cytotoxicity caused by campto-of NF-κB by compound 1 may provide a potential rationale for its enhancement of CPT-induced apoptosis. These findings illustrate that this class of antiapoptotic inhibitors might provide an improved therapeutic strategy in the treatment of cancer.
Results and Discussion

Synthesis of Imidazoline 1
The imidazoline scaffold was prepared via a novel silicon mediated 1,3-dipolar cycloaddition reaction [71, 72] . The low molecular weight scaffold contains a fourpoint diversity applicable to alkyl, aryl, acyl, and heterocyclic substitutions. After screening a small number of Lewis acid, we found that TMSCl promotes the reaction of oxazolones and imines to afford the imidazolines scaffolds in good yields as single diastereomers (Figure 2) .
Compound 1 was isolated as a single diastereomer, and the diastereoselectivity appears to primarily arise from the steric interaction of the bulky silyl group of the azlactone and the phenyl moiety of the imine (Figure 2 ).
Sensitization of Cancer Cells toward Camptothecin
The imidazolines were evaluated for their ability to enhance the activity of camptothecin (CPT) in cancer cells by evaluating the level of apoptosis induced by camp- We describe herein a noncytotoxic agent that drasti-cells with compound 1 did not induce significant amounts of apoptosis (tested up to 10 M for 48 hr by cally enhances the activity of camptothecin in leukemia T cells. This class of NF-κB inhibitors is structurally dif-Apo-ONE as well as by cell count; data not shown). The imidazoline 1 was subsequently screened for its ability ferent from any reported NF-κB inhibitor and unique with respect to its insignificant toxicity and remarkable to enhance apoptosis induced by the chemotherapeutic, camptothecin [40] . ability to enhance the anticancer efficacy of the chemotherapeutic agent camptothecin. The agent was prepared Enhancement of CPT-induced apoptosis in CEM cells was first investigated at concentrations of %10 nM via our recently reported diastereoselective multicomponent one-pot synthesis of imidazolines ( Figure 2) [71, CPT, at which CPT has been reported to cause DNA aberrations but no significant levels of apoptosis in leu-72]. A large library of imidazoline scaffolds was prepared via this silicon-mediated cycloaddition reaction kemia cells [77] . Figure 3 illustrates the effect of the imidazoline on CEM cells when incubated with CPT (10 and evaluated for biological activity. Upon screening of these agents, we found that the imidazoline 1 exhibited nM) over a 48 hr time period. Treatment of the cells with compound 1 (10 nM) had no effect on the level of no apparent cytotoxicity; however, further investigations revealed that this agent drastically enhanced the apoptosis. Treatment of the cells with 10 nM CPT resulted in some cell death starting after 12 hr of drug level of apoptosis induced by chemotherapeutics. Even though micromolar concentrations of compound 1 did treatment. Combination treatment of the noncytotoxic imidazoline 1 (10 nM) with CPT (10 nM) resulted in com-not induce any apoptosis when used as a single agent, it was found to enhance the anticancer efficacy of the plete apoptotic cell death after 48 hr. Additional experiments were performed in order to anticancer agent camptothecin approximately 75-fold at 100 nanomolar concentration. Investigation into its quantify the enhancement of the apoptotic signal in leukemia cells. Briefly, the study was divided into two potential mode of action revealed that the imidazoline blocks the nuclear translocation of NF-κB via the inhibi-sets of experiments, one involving continuous exposure of the agents to the cells, and another subjecting tion of phosphorylated I-κB degradation. The inhibition In order to determine the potential molecular pathway washed with 1× PBS after 1 hr of camptothecin treatthrough which the imidazoline modulates apoptosis, ment, the fold enhancement dropped to 20.9-fold of we evaluated its ability to inhibit CPT induction of NF-CPT-induced cell death (CC 95 ). Similar potentiation was κB activation. Inhibition of the NF-κB signaling cascade seen with pretreatment of ALLN followed by camptomay occur at several different steps in its activation thecin treatment (see Supplemental Figure S2 ). Postpathway ( Figure 1) . In order to determine where the imtreatment of CPT-exposed cells with the imidazoline afidazoline intersected the NF-κB activation pathway, we Figure 6 ). Similar though with varying kinetics [54] . Consistent with these studies, we found that the imidazolines inhibited the results were obtained with HeLa cells activated with TNF-α ( Figure 6) as well as Jurkat cells activated with NF-κB signaling pathway in TNF-α-activated cells more effectively than with CPT, illustrated by an IC 50 value PMA/PHA (data not shown). These findings indicate that imidazoline 1 inhibits the nuclear translocation of of 2.1 nM (see Supplemental Figure S6 ). These studies clearly demonstrate that imidazoline 1 inhibits nuclear NF-κB at the nanomolar level.
activated NF-κB treated with a p65 antibody, which We therefore evaluated imidazoline 1 for its inhibition of the several kinases either related to the NF-κB path-provided a supershift (lane 3), and the unactivated control (lane 4). Treatment of the cells with camptothecin way or other apoptotic signaling pathways. No inhibition of any kinase activity was detected (tested up to 10 resulted in the activation of NF-κB, as indicated by the
. cant inhibition of nuclear translocation after CPT activation (fourth column). Pretreatment of the cells with Similar experiments were performed using TNF-α to activate the leukemia cells. Both TNF-α and CPT are imidazoline 1 30 min prior to activation also resulted in a significant inhibition of translocation (fifth column). Vari-known to activate NF-κB by I-κB degradation following phosphorylation at ser-32 and ser-36 in CEM cells, al-ous concentrations ranges of the imidazoline (1-100 nM) resulted in inhibition of translocation (
translocation of NF-κB via the inhibition of I-κB degradation of TNF-α as well as CPT-activated CEM cells. Inhibition of Kinase Activity
This suggests that the imidazoline may target the 26 
We have demonstrated that imidazoline 1 inhibits the S proteosome or the ubiquitinylation of I-κB. Studies translocation of NF-κB across the nuclear membrane in toward the identification of the potential molecular response to stimulation by camptothecin. The translotarget and its binding interactions are actively ongoing cation of NF-κB requires the phosphorylation and subin our lab. sequent degradation of its inhibitory protein I-κB by the 26 S proteosome, resulting in the liberation of NF-κB [81]. Thus, the effect of the imidazoline on I-κB phos-Inhibition of CPT-Induced NF-B Transcription by Imidazoline 1 phorylation and degradation was investigated. We first evaluated the imidazoline for its effect on the phos-
To demonstrate the ability of imidazoline 1 to affect NF-κB mediated gene transcription, we evaluated the inhi-phorylation of the inhibitory protein I-κB by its endogenous kinases IKKα and IKKβ (data not shown) [ Figure S9 ). signaling pathways, which have compromised the efficacy of these antitumor agents in the clinic. Inhibition of the antiapoptotic transcription factor, NF-B, Luciferase Enzyme Assay To confirm the inhibition of NF-κB-mediated luciferase retards this cellular resistance. We discovered a class of nontoxic agents that drastically enhance the antiproduction by imidazoline 1 and the luciferase enzyme itself, we incubated purified luciferase enzyme with var-tumor efficacy of the chemotherapeutic agent camptothecin. The imidazoline 1 was found to sensitize ious concentrations of imidazoline and vehicle at 0°C 
Apoptosis Assay with Apo-ONE CEM cells (CCRF-CEM; Amer. Type Culture Collection, Rockville, Inhibition of Translocation with p65-ELISA Assay
The quantity of p65/p50 heterodimer that had translocated into the MD) were grown in RPMI-1640 media (Gibco-BRL, Rockville, MD) supplemented with 10% fetal bovine serum, penicillin (614 ng/ml), nucleus was measured using a NF-κB p65 sandwich ELISA assay (Imgenex Corp.). CEM cells were grown to 1.6 × 10 6 cells/ml and streptomycin (10 g/ml), and HEPES buffer (pH 7.2) at 37°C, 5% CO 2 . DMSO was used as the vector for all drugs and was added in were subsequently treated with various concentrations of the compound 1 for 30 min at 37°C and 5% CO 2 followed by TNF 
